Expansion in Thailand for German precision diagnostics firm

We've just kicked off an initiative for Biotype GmbH, part of the Dresden-based Molecular Diagnostics Group, to support its expansion into Thailand.

Biotype is Germany's market leader in haemato-oncology testing. It develops and manufactures in vitro molecular cancer diagnostic test kits which are CE-IVDR-certified, confirming that they meet EU requirements for safety, performance and regulatory compliance.

The company already distributes its products across Europe, and Thailand marks the next step in its international expansion.

Biotype's haemato-oncology portfolio covers key applications in leukaemia diagnostics, chimerism monitoring and molecular profiling, serving clinical laboratories in university hospitals and transplantation centres. It includes products such as Mentype AMLplex, a multiplexed test kit that detects cancer-causing genetic abnormalities during acute myeloid leukaemia (AML) patient screening, and a comprehensive chimerism monitoring range that tracks engraftment success following stem cell transplantation.

Beyond haemato-oncology, Biotype also offers expertise in liquid biopsy and solid tumour diagnostics, underpinned by its proprietary MODAPLEX multiplexing platform.

Biotype is now seeking a distribution partner in Thailand for its haemato-oncology portfolio, targeting clinical university hospitals and medical centres specialising in stem cell transplantation – a sector boosted by the growing medical tourism the country is experiencing.

With a predicted annual growth rate of around 26% until 2032, Thailand's diagnostics test sector is being driven by an ageing population that's increasing the demand for rapid, localised diagnostics. This presents a significant opportunity for Biotype.

Since Thailand's FDA (Food & Drug Administration) recognises internationally-accredited certifications, Biotype's CE-IVDR certification should ease the Thai registration process and reduce the need for additional clinical trials.

Our Bangkok team will be compiling a long list of potential partners for our client, drawing on its existing network and targeted research. Once complete, we'll work with Biotype to evaluate the candidates and create a shortlist of distributors that best meet a set of clearly defined criteria.

Biotype's CEO, Dr Timm Zörgiebel, will visit Thailand in May to meet the companies on the shortlist, supported by our team before, during and after the meetings. This will be followed by selection of a preferred partner or partners and negotiation of a distribution agreement to establish Biotype's presence in the Thai market.

Dr Zörgiebel said: "Precise molecular diagnostics are critical for leukaemia patients – from initial screening through to monitoring the success of a stem cell transplant. Intralink's deep understanding of the Thai healthcare market and their established network of local contacts are exactly what we need to identify the right partner and build a lasting presence in the region."

If you'd like to discuss the prospects for your tech business in Asia, please contact Carsten Detering at carsten.detering@intralinkgroup.com